Europe Human Growth Hormone Market Size Worth USD 3.94 Billion by 2034 | CAGR: 8.1%

The europe human growth hormone market size is expected to reach USD 3.94 Billion by 2034, according to a new study by Polaris Market Research. The report “Europe Human Growth Hormone Market Size, Share, Trends, Industry Analysis Report: By Type (Long-acting, Short-acting & Intermediate-acting), By Route of Administration, By Age, By Disease, By Distribution Channel, By Country – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Human growth hormone is a protein hormone produced by the pituitary gland that stimulates growth, cell reproduction, and regeneration in humans. It plays a crucial role in childhood growth and continues to regulate body composition, muscle and bone growth, and metabolism in adults.

The European Medicines Agency provides a centralized and structured regulatory framework that supports the approval and monitoring of hGH therapies. The region is known for its predictable and science-based regulatory environment, which encourages pharmaceutical companies to invest in hGH development. The EMA further promotes the safe adoption of biosimilars, increasing treatment accessibility. Additionally, EU initiatives supporting rare disease therapies and orphan drugs create favorable conditions for launching new hGH treatments. This supportive regulatory landscape helps accelerate the introduction of new products and ensures high treatment standards across Europe.

Bottom of Form

Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/europe-human-growth-hormone-market/request-for-sample

The increasing availability and acceptance of biosimilar human growth hormone products are accelerating market expansion in Europe. The European Medicines Agency was among the first regulators globally to approve biosimilars, creating a favorable environment for their adoption. Countries across Europe are promoting the use of biosimilars to reduce healthcare spending while maintaining treatment quality. Biosimilar help make hGH therapy affordable for a larger population as they become more accessible. This increased affordability and physician confidence in biosimilars are fueling the penetration and driving competition among manufacturers.

Europe Human Growth Hormone Market Report Highlights

• The long-acting segment is expected to grow at a CAGR of 9.5% during the forecast period, driven by its enhanced convenience and improved patient adherence compared to daily injections.
• In 2024, the online pharmacies segment accounted for 14.90% of the revenue, reflecting the rapid shift toward digital health in Europe, especially following the COVID-19 pandemic, which accelerated the adoption of online platforms for hGH distribution.
• Germany captured 22.28% of the global human growth hormone market revenue in 2024, supported by its advanced healthcare infrastructure, comprehensive insurance coverage, and early integration of innovative hGH therapies.
• France held an 18.03% share of the European market in 2024, owing to its strong public healthcare system and robust government reimbursement policies that promote access to hormone treatments.
• The global key market players are AnkeBio Co., Ltd; Ascendis Pharma; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; Ferring Pharmaceuticals; Merck KGaA; Novo Nordisk A/S; Pfizer Inc; Sandoz Inc.; Teva Pharmaceuticals USA, Inc.

Polaris market research has segmented the Europe Human Growth Hormone Market report based on type, route of administration, age, disease, distribution channel, and country:

By Type (Revenue - USD Billion, 2020–2034)

• Long-acting
• Short-acting & Intermediate-acting

By Route of Administration (Revenue - USD Billion, 2020–2034)

• Oral
• Parenteral
  • Intravenous
  • Subcutaneous
  • Intramuscular

By Age (Revenue - USD Billion, 2020–2034)

• Pediatric
• Adult

By Disease (Revenue - USD Billion, 2020–2034)

• Growth Hormone Deficiency
  • Pediatric GHD
  • Adult GHD
• Turner Syndrome
• Idiopathic Short Stature
• Prader-Willi Syndrome
• Others

By Distribution Channel (Revenue - USD Billion, 2020–2034)

• Hospital Pharmacies
• Retail Pharmacies & Drug Stores
• Online Pharmacies

By Regional Outlook (Revenue - USD Billion, 2020–2034)

• Germany
• UK
• France
• Italy
• Spain
• Russia
• Netherlands
• Rest of Europe